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Abstract
Context/objectives This is the first study to determine the minimal clinically important difference (MCID) of the European
Organisation of Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale (EORTC QLQ-
CIPN20), a validated instrument designed to elicit cancer patients’ experience of symptoms and functional limitations related
to chemotherapy-induced peripheral neuropathy.
Methods Cancer patients receiving neurotoxic chemotherapy completed EORTC QLQ-CIPN20 and the Functional Assessment
of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity [FACT/GOG-NTX] at baseline, second cycle of chemotherapy
(T2, n = 287), and 12 months after chemotherapy (T3, n = 191). Anchor-based approach used the validated FACT/GOG-NTX
neurotoxicity (Ntx) subscale to identify optimal MCID cutoff for deterioration. Distribution-based approach used one-third
standard deviation (SD), half SD, and one standard error of measurement of the total EORTC QLQ-CIPN20 score.
Results There was a moderate correlation between the change scores of the Ntx subscale and sensory and motor subscales of
QLQ-CIPN20 (T2: r = − 0.722, p < 0.001 and r = − 0.518, p < 0.001, respectively; T3: r = − 0.699; p < 0.001 and r = − 0.523,
p < 0.001, respectively). The correlation between the change scores of the Ntx subscale and the QLQ-CIPN20 autonomic
subscale was poor (T2: r = − 0.354, p < 0.001; T3: r = 0.286, p < 0.001). Based on the MCID derived using distribution-based
method, the MCID for the QLQ-CIPN20 sensory subscale was 2.5–5.9 (6.9% to 16.4% of the subdomain score) and for motor
subscale was 2.6–5.0 (8.1%–15.6% of the subdomain score).
Conclusion The MCID for the EORTC QLQ-CIPN20 established using distribution-based approaches was 2.5–5.9 for the
sensory subscale and 2.6–5.0 for the motor subscale. When noted in assessments even with small change in scores, clinicians
can be alerted for appropriate intervention.
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Introduction
Chemotherapy-induced peripheral neurotoxicity (CIPN) is
one of the prevalent non-hematological adverse effects and
can greatly impact patients’ treatment outcomes [1]. CIPN is
also a major cause of significant distress in cancer patients and
can be associated with decreased quality of life, reduced func-
tional ability, and increased risk for falls. A number of cyto-
toxic chemotherapy agents are associated with peripheral neu-
ropathy, and these agents include taxanes, platinums, vinca
alkaloids, and bortezomib [2, 3]. Although a number of agents
have been investigated for the management of CIPN, effective
agents for managing such debilitating toxicity are extremely
limited [4].
In order to study the impact of CIPN on quality of life, in
clinical studies, a number of assessment tools have been used
on oncology patients receiving chemotherapy. Assessments of
CIPN include the use of objective measurements (e.g., nerve
conduction studies [5, 6]), clinician-assessed outcomes (e.g.,
NCI-CTCAE [2, 7]), patient-reported outcomes (PRO) scores
[8, 9], and even composite scores using a combination of
nerve conduction studies and patient-reported outcome scores
(e.g., total neuropathy score [TNS] [10]). In the literature, it is
recognized that PRO measures of sensory CIPN are preferred
over clinician-determined assessments [11]. PRO tools that
are commonly used include the European Organization of
Research and Treatment of Cancer Quality of Life
Questionnaire-CIPN twenty-item scale (EORTC QLQ-
CIPN20) and the Functional Assessment of Cancer Therapy/
Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-
NTX) tools [12, 13].
Clinicians can utilize PRO tools longitudinally to monitor
patients’ CIPN symptoms over the course of treatment.
However, depending on the statistical tests alone to determine
statistically meaningful difference in CIPN scores might be of
little clinical relevance to patients and would not be applicable
in daily clinical practice. In such situations, the minimal clin-
ically important difference of CIPN scores would be valuable.
The MCID is defined as the smallest difference in score that
patients perceive as beneficial and that would mandate a
change in the patient’s management, which also represents
the smallest change in score in which symptom worsening is
clinically significant [14, 15].
The MCID of EORTC QLQ-CIPN20 has not been
established in the literature. There is great clinical utility with
establishing the MCID. Patients whose change in clinical neu-
ropathy score exceeds the MCID of the EORTC QLQ-
CIPN20 could benefit from active and timely management
of their neuropathy symptoms. In addition, the MCID of the
EORTC QLQ-CIPN20 can be potentially used to establish
adjunctive treatment recommendations for future patients with
cancer or to determine sample size estimates of future clinical
trials on CIPN management.
In view of the lack of the MCID of EORTC QLQ-CIPN20,
we have designed a study to determine the MCID of EORTC
QLQ-CIPN20 among patients receiving neurotoxic
chemotherapy.
Materials and methods
Study setting and population
This is a secondary analysis of a prospective study conducted
at both inpatient and outpatient oncology units of three hospi-
tals located in Hong Kong, Singapore, and United Kingdom
[16]. All eligible patients must be (1) ≥ 18 years old, (2) diag-
nosed with cancer by a medical oncologist, (3) chemotherapy-
naïve, (4) planned to receive taxane- and/or platinum-based
chemotherapy, (5) have an expected survival of at least
12 months, and (6) able to provide informed consent.
Study procedure
At the point of recruitment, patient’s demographic and clinical
information such as age, cancer history, and cancer treatment
history were collected from existing in-house electronic data-
bases and patients’ interview. Two quality of life question-
naires, EORTC QLQ-CIPN20 and FACT/GOG-NTX, were
administered at baseline (namely timepoint 1, or T1), at sec-
ond cycle of chemotherapy (namely timepoint 2, or T2) after
chemotherapy initiation and at 12-month follow-up after che-
motherapy initiation (namely timepoint 3, or T3). Generally,
T2 and T3 occurred 3weeks and 12months, respectively, after
baseline. These timepoints were chosen to compare the
change of neuropathy symptoms after exposure to neurotoxic
chemotherapy on baseline.
Instruments
The Functional Assessment of Cancer Therapy/Gynecologic
Oncology Group-Neurotoxicity [FACT/GOG-NTX] is a 38-
item self-reported questionnaire comprising two subscales,
the first being a 27-item general assessment of quality of life
subscale and the second being an 11-item neurotoxicity (Ntx)
subscale that evaluates symptoms associated specifically with
chemotherapy-induced neuropathy [17]. All items are linearly
converted to a 0–152 scale with higher scores suggestive of a
better quality of life.
The European Organisation of Research and Treatment of
Cancer Quality of Life Questionnaire-CIPN twenty-item scale
[EORTC QLQ-CIPN20] is a 20-item questionnaire that as-
sesses the severity of neuropathy symptoms experienced by
patients [18]. It comprises three domains: sensory (nine
items), motor (eight items), and autonomic (three items) sub-
scales. With a 4-point Likert scale (1 = not at all, 2 = a little,
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3 = quite a bit, and 4 = very much), patients will rate their
symptoms during the past week. Sensory scale scores range
from 1 to 36, motor scale scores range from 1 to 32, and
autonomic scale scores range from 1 to 12 for men and 1–8
for women (erect dysfunction item excluded). All items are
linearly converted to a 0–100 scale with higher scores indica-
tive of more symptoms. In the Caucasian population, the
EORTC QLQ-CIPN20 is also a validated tool that demon-
strated good internal consistency reliability based on
Cronbach’s alpha coefficients of 0.88, 0.88, and 0.78 for the
sensory, motor, and autonomic scales, respectively [19].
Statistical analysis
To compare the EORTC-QLQ-CIPN20 and FACT/GOG-
NTX scores across (i) baseline and T2 and (ii) baseline and
T3, a paired t test was used. The MCID of the EORTC-QLQ-
CIPN20 was determined using anchor-based and distribution-
based approaches [20, 21]. The SPSS software Version 24.0
for Windows was used for the statistical analysis.
Anchor-based approach
The Ntx-subscale of FACT/GOG-NTX was used as an exter-
nal criterion against which changes in EORTC QLQ-CIPN20
were anchored and calibrated. Spearman rank correlation co-
efficient was used to quantify the association between EORTC
QLQ-CIPN20 and Ntx subscale. To establish an MCID, it has
been recommended that the change scores of the anchor and
the instrument being examined have a correlation threshold of
r > 0.30 [22]. We have previously validated and confirmed the
psychometric properties of QLQ-CIPN20 in the Asian popu-
lation, the research group conducted a separate study that in-
cluded a cohort of oncology patients from Hong Kong,
Singapore, and United Kingdom. In the study, EORTC
QLQ-CIPN20 sensory and motor scores were moderately cor-
related with NCI CTCAE sensory (r = 0.46) and motor scores
(r = 0.52) respectively, suggesting concurrent validity. Good
internal consistency reliability was also observed with
Cronbach’s alpha coefficients of 0.79 and 0.47 for the sensory
and motor scales, respectively (unpublished).
Although there is no MCID established for FACT/GOG-
NTX, it is a validated PRO tool and the NTX-subscale corre-
lates highly with both the objective and subjective neuropathy
assessments [17, 23]. Therefore, in this study, we define a 3.3–
4.4 point change of the subscale score as clinically important
change in the 11-item NTX subscale of FACT/GOG-NTX.
This is based on current recommendations that the general
minimally important difference for Functional Assessment
of Chronic Illness Therapy (FACIT) cancer-specific subscales
is 0.3 to 0.4 point change per item, and previous studies that
have also utilized similar approaches on anchoring with
FACIT’s questionnaires [20]. To obtain the MCID for
deterioration, the mean difference in scores for “no change”
was subtracted from the mean difference in scores for “dete-
rioration by at least one category.” Likewise, the average dif-
ference scores for patients classified as “improvement by at
least one category”were compared with those for “no change”
to compute the MCID estimate for improvement. The associ-
ated effect sizes (ESs) were determined for the respective clin-
ical categories by dividing the mean change in scores by the
overall baseline standard deviations (SDs) for the sample. The
ES determines the responsiveness of the EORTC QLQ-
CIPN20 to changes in neuropathy symptoms. An ES of 0.2,
0.5, and 0.8 is considered to be small, moderate, and large,
respectively. A threshold of ES < 0.2 was used to exclude
MCID estimates too small to be interpreted [24].
Distribution-based approach
The magnitude of MCID for EORTC QLQ-CIPN20 scores
was estimated using effect sizes (ES). An ES is a standardized
index of change that represents the number of SDs by which
the scores have changed from T1-T2 and T1-T3. MCID de-
terminant studies for FACIT and EORTC QLQ instruments
show that one-third and half SDs closely approximate the
MCID [25, 26]. Thus, one-third and half SDs were calculated
at T1, T2, T3, T1-T2 score changes and for T1-T3 score
changes. Additionally, the standard error of measurement
(SEM) was used to calculate the MCID estimate. A one
SEM is considered to likely approximation of the MCID
[25–27]. The one-SEM value was computed using the follow-
ing formula: SEM= σ√(1-r), where σ = the SD of the EORTC
QLQ-CIPN20 scores and r = the mean test-retest reliability of
the instrument. The r value taken to calculate one SEM was
0.836, 0.844, and 0.726 for sensory, motor, and autonomic
subscales, respectively [28].
Estimation of the overall MCID
Instead of estimating the MCID as an absolute single thresh-
old, Hays et al. [29] suggested to combine a possible range of
MCIDs to accommodate for the method- and sample-
dependent variations. Therefore, the estimated value range
was achieved by combining the MCID values obtained from
the aforementioned anchor-based and distribution-based
approaches.
Results
Demographics
At T1, 343 patients were recruited, with mean age of 55 years
(SD = 9.4) (Table 1). At T2 and T3, 287 (mean age 55 years
(SD = 9.2)) and 191 (mean age 56 years (SD = 9.2)) patients,
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respectively, remained in the study. The vast majority were
female (T1 = 74.6%, T2 = 77.4%, T3 = 74.9%) and had stages
I–III cancer (T1 = 77.9%, T2 = 79.8%, T3 = 75.4%). At T1,
T2, and T3, 174 (50.7%), 159 (55.4%), and 103 (53.9%) pa-
tients, respectively, were diagnosed with breast cancer, re-
ceived adjuvant chemotherapy (T1 = 58%, T2 = 61.3%,
T3 = 55%). Taxane-based chemotherapy (T1 = 45.2%, T2 =
48.8%, T3 = 48.7%) was the most commonly used chemo-
therapeutic protocol among patients.
Questionnaire scoring
The score distributions for the FACT/GOG-NTX for T1-T2
and T1-T3 are summarized in Table 2. The mean (±SD) total
FACT/GOG-NTX scores at T1 and T2 were 126.9 ± 18.4 and
123.9 ± 20.8, respectively, with an average change of − 3.04 ±
19.4 (p = 0.008). The mean (±SD) total FACT/GOG-NTX
scores at T1 and T3 were 129.5 ± 16.6 and 134.2 ± 16.9, re-
spectively, with an average change of 4.8 ± 16.7 (p < 0.001).
The score distributions for the EORTC QLQ-CIPN20 for
T1-T2 and T1-T3 are summarized in Table 3. For the sensory
domain, the mean (±SD) scores at baseline and cycle 2 were
2.9 ± 7.4 and 7.8 ± 13.5, respectively, with an average change
of 4.8 ± 14.2 (p < 0.001). For the motor domain, the mean
(±SD) scores at baseline and cycle 2 were 3.4 ± 6.7 and 5.9
± 11.4, respectively, with an average change of 2.5 ± 11.7
(p < 0.001). For the autonomic domain, the mean (±SD) auto-
nomic domain scores at baseline and cycle 2 were 7 ± 13.4
and 9.2 ± 15.4, respectively, with an average change of 2.2 ±
15.8 (p = 0.019). For the sensory domain, the mean (±SD)
scores at baseline and T3 were 2.3 ± 5.0 and 6.4 ± 10.1, re-
spectively, with an average change of 4.0 ± 9.4 (p < 0.001).
For the motor domain, the mean (±SD) scores at baseline
and T3 were 2.9 ± 6.0 and 5.3 ± 10.2, respectively, with an
average change of 2.4 ± 10.0 (p = 0.001). For the autonomic
domain, the average change of mean (±SD) scores was found
to be statistically insignificant (p = 0.943).
Anchor-based analysis
At T2, there was a moderate correlation between the change
scores of the FACT/GOG-NTX Ntx subscale and sensory
scale and motor scale of EORTC QLQ-CIPN20 (r = − 0.722,
p < 0.001 and r = − 0.518, p < 0.001, respectively). However,
the correlation between the change scores of the FACT/GOG-
NTX Ntx subscale and the autonomic scale of EORTC QLQ-
CIPN20 was poor (r = − 0.354, p < 0.001). A decrease of 4.9
points (95% CI: 1.3–8.5; ES = 0.66) of the sensory scale
Table 1 Patients’ characteristics and demographics
Demographics Baseline, T1 (n = 343) 3 weeks after baseline, T2 (n = 287) 12 months after baseline, T3 (n = 191)
Age (year), mean (SD) 55 (9.4) 55 (9.2) 56 (9.2)
Gender, n (%)
Female 256 (74.6) 222 (77.4) 143 (74.9)
Male 87 (25.4) 65 (22.6) 48 (25.1)
Cancer diagnosis, n (%)
Breast 174 (50.7) 159 (55.4) 103 (53.9)
Lung 48 (14.0) 32 (11.2) 18 (9.4)
Ovarian 32 (9.3) 25 (8.7) 18 (9.4)
Others 89 (26.0) 71 (24.7) 52 (27.3)
Cancer stage, n (%)
I 52 (15.2) 45 (15.7) 32 (16.8)
II 99 (28.9) 91 (31.7) 53 (27.7)
III 116 (33.8) 93 (32.4) 59 (30.9)
IV 76 (22.2) 58 (20.2) 47 (24.6)
Treatment intent
Adjuvant 199 (58.0) 176 (61.3) 105 (55)
Neoadjuvant 51 (14.9) 46 (16) 30 (15.7)
Concurrent 30 (8.7) 17 (6) 16 (8.4)
Palliative 63 (18.4) 48 (16.7) 40 (20.9)
Chemotherapy Regimen, n (%)
Taxane 155 (45.2) 140 (48.8) 93 (48.7)
Platinum 109 (31.8) 80 (27.9) 55 (28.8)
Combined taxane and platinum 79 (23.0) 67 (23.3) 43 (22.5)
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corresponded to a minimal important change, and the value
was statistically significant (Table 4). Conversely, a decrease
of 1.6 (95% CI: − 1.7–4.8) and 6.7 points (95% CI: − 1.0–
14.3) of the motor and autonomic scales, respectively,
corresponded to a minimal importance change, but both the
values were statistically insignificant. Hence, a minimal im-
portance change could not be established with the motor and
autonomic scales at T2.
At T3, there was a moderate correlation between the
change scores of the FACT/GOG-NTX Ntx subscale and
sensory scale and motor scale of EORTC QLQ-CIPN20
(r = − 0.699, p < 0.001 and r = − 0.523, p < 0.001, respec-
tively). In contrast, the correlation between the change scores
of the FACT/GOG-NTX Ntx subscale and the autonomic
scale of EORTC QLQ-CIPN20 was poor (r = 0.286,
p < 0.001). A decrease of 13.6 points (95% CI: 3.2–24;
ES = 2.72) of the sensory subscale and a decrease of 4.2
points (95% CI: 1.4–7.0; ES = 0.70) of the motor
corresponded to a minimal important change, and both
values were statistically significant (Table 4). In contrast, a
decrease of 5.6 points (95% CI: − 5.5–16.7) of the autonomic
scale corresponded to a minimal importance change, but the
mean change was not statistically significant. Therefore, a
minimal importance change could not be established with
the autonomic subscale.
Although the 95% CI range for sensory subscale over-
lapped between T2 (1.3–8.5) and T3 (3.2–24), the mean
change scores were found to vary at these timepoints (4.9
points versus 13.6 points). For motor subscale, there was an
overlapping of 95% CI range between T2 (− 1.7–4.8) and T3
(1.4–7.0) with similar mean change scores (1.6 points versus
4.2 points). However, the mean score change of motor sub-
scale at T2 was found to be not statistically significant.
Therefore, similar to the autonomic subscale, the MCID for
Table 2 FACT/GOG-NTX scores at (i) baseline (T1) and T2 (3 weeks after baseline, n = 287) and (ii) T1 and T3 (12 months after baseline, n = 191)
Domains Baseline (T1) (mean [SD]) T2 or T3 (mean [SD]) Average change (mean [SD]), p value
T1 and T2
Physical well-being (score 0–28) 24.3 [4.4] 23.3 [5.9] − 1.06 [6.2], 0.004
Social/Family well-being (score 0–28) 23.7 [5.8] 22.8 [6.3] − 0.95 [5.9], 0.007
Emotional well-being (score 0–24) 18.2 [4.3] 19.6 [3.8] 1.4 [3.9], < 0.001
Functional well-being (score 0–28) 18.4 [7.5] 18 [7.2] − 0.49 [7.5], 0.269
Neurotoxicity (Ntx) subscale (score 0–44) 42.2 [3.5] 40.3 [5.7] − 1.93 [5.9], < 0.001
FACT/GOG-NTX total score (score 0–152) 126.9 [18.4] 123.9 [20.8] − 3.04 [19.4], 0.008
T1 and T3
Physical well-being (score 0–28) 24.7 [4.0] 25.7 [3.9] 1.0 [3.9], < 0.001
Social/Family well-being (score 0–28) 24.6 [5.1] 23.6 [5.5] − 1.0 [5.3], 0.011
Emotional well-being (score 0–24) 18.6 [4.4] 21.2 [3.4] 2.6 [4.5], < 0.001
Functional well-being (score 0–28) 19.1 [6.9] 23.1 [5.4] 4.0 [7.5], < 0.001
Neurotoxicity (Ntx) subscale (score 0–44) 42.5 [2.9] 40.7 [4.9] − 1.9 [4.5], < 0.001
FACT/GOG-NTX total score (score 0–152) 129.5 [16.6] 134.2 [16.9] 4.8 [16.7], < 0.001
All data presented as mean [SD]
Higher scores in the FACT/GOG-NTX indicative of better quality of life
Table 3 EORTC QLQ-CIPN20 scores at (i) baseline (T1) and T2 (3 weeks after baseline, n = 287) and (ii) T1 and T3 (12 months after baseline, n =
191)
Domain Baseline (T1) (mean [SD]) T2 or T3 (mean [SD]) Average change (mean [SD]), p value
T1 and T2
Sensory 2.9 [7.4] 7.8 [13.5] 4.8 [14.2], < 0.001
Motor 3.4 [6.7] 5.9 [11.4] 2.5 [11.7], < 0.001
Autonomic 7 [13.4] 9.2 [15.4] 2.2 [15.8], 0.019
T1 and T3
Sensory 2.3 [5.0] 6.4 [10.1] 4.0 [9.4], < 0.001
Motor 2.9 [6.0] 5.3 [10.2] 2.4 [10.0], 0.001
Autonomic 7.4 [13.6] 7.3 [13.8] − 0.1 [16.8], 0.943
All data presented as mean [SD]; all items are linearly converted to a 0–100 scale with higher scores indicative of more symptoms
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both sensory and motor subscales could not be established
using the anchor-based approach.
Distribution-based analysis
At T2, the calculated means for one-third of the SD and half of
the SD produced MCID estimates for the sensory, motor, and
autonomic subscales that ranged from 3.5 to 5.9, 3.0 to 5.0,
and 4.5 to 7.5, respectively (Table 5). TheMCID derived from
the value of one SEMwas 4.8 for the sensory subscale, 3.9 for
the motor subscale, and 7.8 for the autonomic subscale.
At T3, the calculated means for one-third of the SD and
half of the SD produced MCID estimates for the sensory,
motor, and autonomic subscales that ranged from 2.5 to 4.1,
2.6 to 4.4, and 4.4 to 7.4, respectively. The MCID derived
from the value of one SEM was 3.3 for the sensory subscale,
3.5 for the motor subscale, and 7.7 for the autonomic subscale
(Table 5).
Altogether, the calculated MCID ranges for the sensory,
motor, and autonomic subscales were found to overlap be-
tween T2 and T3. The acceptable range for sensory subscale
and motor subscale was 2.5–5.9 and 2.6–5.0, respectively. As
the mean change score for autonomic subscale between T1
and T3 was not statistically significant (Table 3), the MCID
for this subscale could not be established from the
distribution-based approach.
Estimation of the overall MCID
Based on the study, the MCID derived using distribution-
based method for the QLQ-CIPN20 sensory subscale was
2.5–5.9 and for motor subscale was 2.6–5.0. The MCIDs de-
rived from the anchor-based analysis for sensory, motor, and
autonomic subscales at T2 and T3 were excluded as they were
found to be either inconsistent or not statistically significant.
Discussion
To our knowledge, this is the first study to establish the MCID
of EORTC QLQ-CIPN20. We determine the MCID based on
the neuropathic symptoms that occur at second cycle of che-
motherapy as well as 12-month follow-up after chemotherapy
initiation. Based on the distribution-based approach, the se-
verity of symptoms at both timepoints was found to be similar.
This finding may indicate that the clinically relevant changes
can be captured at the early stage of chemotherapy (second
cycle) for calculation of the MCID so that appropriate inter-
ventions can be made based on clinically relevant neurotoxic-
ity, which include dose modification or therapy alteration.
Through our findings, we ascertain that an increase between
2.5 and 5.9 points on the QLQ-CIPN20 sensory subscale and
2.6 to 5.0 points on the QLQ-CIPN20 motor subscale are
considered to be the smallest clinically important change.
This is important as this would also suggest that increase of
such scores may require active interventions by clinicians to
manage the neuropathy. The outcome of the study was within
our expectations as taxane- and platinum-based chemotherapy
received by the cancer patients (Table 1) are known to cause
peripheral neuropathy [30, 31]. Unfortunately, using the
anchor-based analysis, we were unable to establish the
MCID for the autonomic subscale as the mean change at T2
and T3 was not statistically significant (Table 4) to merit con-
sideration. In addition, the mean change between T1 and T3
for the autonomic subscale was found to be statistically insig-
nificant (Table 3). Therefore, theMCID for this subscale could
not be established using distribution-based approach.
For PRO tools, there is a rule of thumb that a change of
approximately 10% of the total score can be considered as
clinically significant [32]. In this study, we observed that a
change of sensory subscale by 6.9% to 16.4% of the total
score and a change of the motor subscale by 8.1% to 15.6%
of the total score of QLQ-CIPN20 are being considered as
clinically important. It can be interpreted that patients are
more sensitive with the onset of their sensory symptoms,
which as a result, a smaller percentage change of the total
score was classified as clinically significant as compared to
the percentage change of the motor subscale. Recently, PRO
tools have been increasingly incorporated in clinical setting as
they are inferred to influence the treatment process and im-
prove outcome of care [33, 34]. Participants recruited in our
study are a representation of the patients that are encountered
in our clinical practice based on the treatment and dose re-
ceived for their chemotherapy. Therefore, the established
MCID for sensory and motor subscales of QLQ-CIPN 20 in
this study can be of a useful tool in both research and clinical
settings to assist with clinical care.
Using QLQ-CIPN20, it is also recognized that patients ex-
perienced more sensory CIPN symptoms as compared to motor
CIPN symptoms. When we examine carefully on the symp-
toms that are assessed under the sensory subscales of QLQ-
CIPN20, it examines how neuropathic symptoms impact phys-
ical activity of daily living, which include whether one is hav-
ing (1) tingling, numbness, or burning pain in hands or feet; (2)
problem standing or walking; (3) difficulty distinguishing hot
and cold water; and (4) difficulty hearing [19]. As these symp-
toms could create a lot of negative impact to patients when they
occur, this would rationalize why patients experiencing any
slight bit of these sensory symptoms would consider those
symptoms as clinically important. However, it is important to
note that definitions of sensory neuropathy have not been con-
sistent across the literature. For example, the National Institute
of Neurological Diseases provides a definition on peripheral
neuropathy that is distinctly different from QLQ-CIPN20
[35], and they identify sensory nerve damage as poor coordi-
nation of complex movements including walking or fastening
Support Care Cancer
buttons or coordinating balances when eyes are shut. However,
muscle weakness is the most commonly associated symptom
with motor neuropathy, as well as other symptoms such as
painful cramps and fasciculation, muscle atrophy, and decrease
reflexes. Yet, these motor symptoms are being classified as
sensory neuropathy symptoms using the QLQ-CIPN20.
Hence, further evaluation of the appropriateness of the symp-
tom items within the QLQ-CIPN20 scales through psychomet-
ric studies would be required.
Our study showed that the MCID ranges derived from the
distribution-based approachwere consistent across T2 and T3.
However, this was not the case using the anchor-based ap-
proach (Table 4). In the latter approach, we were unable to
establish the MCID for sensory subscale as mean change
scores varied between T2 and T3 and that the effect size at
T3 was too large (ES = 2.72). In addition, the mean change
score for motor subscale at T2 was found to be not statistically
significant. In the current study, the defined MCID of 3.3–4.4
point change for the 11-item NTX-subscale of FACT/GOG-
NTX is based on the general recommendations of FACIT
cancer-specific subscales (Yost and Eton 2005). As a result,
this may have generated inconsistencies of the aforemen-
tioned results. Additionally, due to the small number of iden-
tified patients who experienced a deterioration (n = 15 for T2;
n = 9 for T3) based on the FACT/GOG-NTX NTX-subscale,
the width of confidence intervals produced were large,
resulting in less precise estimates for the mean change scores
of the QLQ-CIPN20 subscales between T2 and T3. The pre-
cision of the results could be improved using a larger sample
size. Hence, we established the MCID using the distribution-
based approach in this study. The MCID derived from the
distribution-based approach in the current study is deemed
Table 4 Anchor-based approach to estimate the MCID of EORTC QLQ-CIPN20 at (i) T2 and (ii) T3
T2 (3 weeks after baseline)
Improved by at least one categorya No change Deterioration by at least one categorya
Ntx-subscale n = 3 n = 210 n = 15
QLQ-CIPN20-sensory subscale
Mean change score
(95% CI)
− 4.9
(− 15.7 to 5.7)
1.3
(0.7 to 2.0)
4.9
(1.3 to 8.5)
Effect size 0.66 0.18 0.66
QLQ-CIPN20-motor subscale
Mean change score (95% CI) − 9.5
(− 40.8 to 21.8)
− 0.0
(− 0.7 to 0.6)
1.6
(− 1.7 to 4.8)
Effect size 1.42 0 0.24
QLQ-CIPN20-autonomic subscale
Mean change score (95% CI) − 5.6
(− 29.5 to 18.3)
− 0.2
(− 1.4 to 1.1)
6.7
(− 1.0 to 14.3)
Effect size 0.42 0.01 0.50
T3 (12 months after baseline)
Improved by at least one categorya No change Deterioration by at least one categorya
Ntx subscale n = 5 n = 132 n = 9
QLQ-CIPN20-sensory subscale
Mean change score (95% CI) − 5.2
(− 10.4 to 0.06)
0.8
(0.03 to 1.6)
13.6
(3.2 to 24)
Effect size 1.04 0.16 2.72
QLQ-CIPN20-motor subscale
Mean change score (95% CI) − 7.6
(− 16.6 to 1.3)
0.5
(− 0.6 to 1.5)
4.2
(1.4 to 7.0)
Effect size 1.27 0.08 0.70
QLQ-CIPN20 autonomic subscale
Mean change score (95% CI) − 13.3
(− 31 to 4.0)
− 1.3
(− 3.2 to 0.7)
5.6
(− 5.5 to 16.7)
Effect size 0.98 0.10 0.41
Timepoint chosen: T2 and T3
aOne category refers to a 3.3 to 4.4 point change in Ntx subscale scores [20]
Assumption: MCID for Ntx subscale is 3.3 to 4.4
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reliable as similar studies [36, 37] have shown that anchor-
based and distribution-based approaches yielded similar
MCID range. Currently, there is no consensus on the most
appropriate method to calculate the MCID. There is literature
that advocates the use of distribution-based approach, as it
utilizes statistical property of a data set to establish the appro-
priate MCID. Both anchor- and distribution-based approaches
have both been reported as viable options for computations.
Therefore, in our study, we applied the FACT/GOG-NTXNtx
subscale as an external anchor that accounts for the changes in
neuropathy symptoms perceived by the patient. On the con-
trary, the distribution-based methods allow one to examine the
precision of the measurement.
We observed a moderate correlation of the Ntx-subscale
with sensory and motor scales of QLQ-CIPN20. However,
the correlation between the change scores of the Ntx sub-
scale and the autonomic subscale of QLQ-CIPN20 was
poor. This could be because there were only three items
in the QLQ-CIPN20 instrument assessing autonomic func-
tion, and the Ntx subscale does not assess neuropathy
symptoms that are presented as dizziness or blurred vision,
making it a poor anchor to establish with the autonomic
subscale of QLQ-CIPN20. Our finding was found to be
consistent to a previous study investigating the relationship
between the FACT/GOG-NTx Ntx subscale, and sensory,
motor, and autonomic subscales of pin test [17]. Lavoie
et al. [19] demonstrated the reliability and validity in the
sensory and motor subscales of QLQ-CIPN20. However,
the autonomic subscale items were found to be not aligned
with symptom severity [38] and showed low item-item
correlations (r < 0.30) [19]. Future studies would need to
utilize a more specific symptom tool (such as Rotterdam
Symptom Checklist) that is able to assess autonomic symp-
toms, which could be a better tool to assess autonomic
symptoms. In addition, future prospective studies should
examine the correlation between the QLQ-CIPN20/FACT/
GOG-NTX score change and dose change/dose delays/reg-
imen change, so that dose change/dose delays/regimen
change-based MCID could be established for QLQ-
CIPN20/FACT/GOG-NTX. Future studies can examine
the impact of dose titration based on recommended
MCID for QLQ-CIPN20 as proposed in our study.
Table 5 Distribution-based approach to estimate the MCID of EORTCQLQ-CIPN20 at (i) T1 (baseline) and T2 (3 weeks after baseline, n = 287) and
(ii) T1 (baseline) and T3 (12 months after baseline, n = 191)
QLQ-CIPN20-sensory subscale
T1 and T2 T1 and T3
SD 0.3 SD 0.5 SD 1 SEM SD 0.3 SD 0.5 SD 1 SEM
Baseline (T1) 7.37 2.21 3.69 2.98 Baseline (T1) 5 1.50 2.50 2.02
T2 13.56 4.07 6.78 5.49 T3 10.1 3.03 5.05 4.09
Change from T1 to T2 14.23 4.27 7.12 5.76 Change from T1 to T3 9.4 2.82 4.70 3.81
Mean 11.72 3.52 5.86 4.75 Mean 8.17 2.45 4.08 3.31
aReliability value used to calculate 1 SEM was 0.836
QLQ-CIPN20-motor subscale
T1 and T2 T1 and T3
SD 0.3 SD 0.5 SD 1 SEM SD 0.3 SD 0.5 SD 1 SEM
Baseline (T1) 6.68 2.00 3.34 2.64 Baseline (T1) 6 1.80 3.00 2.37
T2 11.44 3.43 5.72 4.52 T3 10.2 3.06 5.10 4.03
Change from T1 to T2 11.71 3.51 5.86 4.63 Change from T1 to T3 10 3.00 5.00 3.95
Mean 9.94 2.98 4.97 3.93 Mean 8.73 2.62 4.37 3.45
aReliability value used to calculate 1 SEM was 0.844
QLQ-CIPN20-autonomic subscale
T1 and T2 T1 and T3
SD 0.3 SD 0.5 SD 1 SEM SD 0.3 SD 0.5 SD 1 SEM
Baseline (T1) 13.36 4.01 6.68 6.99 Baseline (T1) 13.6 4.08 6.80 7.12
T2 15.63 4.69 7.82 8.18 T3 13.8 4.14 6.90 7.22
Change from T1 to T2 15.8 4.74 7.90 8.27 Change from T1 to T3 16.8 5.04 8.40 8.79
Mean 14.93 4.48 7.47 7.81 Mean 14.73 4.42 7.37 7.71
aReliability value used to calculate 1 SEM was 0.726
Timepoint chosen: T1 and T2; T1 and T3
a Test-retest reliability (r) value taken to calculate 1 SEM was 0.836 for sensory subscale, 0.844 for motor subscale, and 0.726 for autonomic subscale [28]
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There are some limitations with this study. One may also
argue whether it is more appropriate to utilize the total score
generated from FACT/GOG-NTX, rather than the Ntx sub-
scale, to serve as the anchor in our anchor-based analysis.
The items described in other subdomains apart from Ntx sub-
scale possess very little relevance to peripheral neuropathy
symptom; hence, it may not have been suitable to utilize the
total score. However, we could not establish MCID for QLQ-
CIPN20 sensory, motor, and autonomic subscales. Thus, fu-
ture studies may need to identify another anchor that is more
appropriate to determine the MCID of the QLQ-CIPN20 sub-
scales. Lastly, majority of the patients are breast cancer pa-
tients receiving taxane-based chemotherapy, which may make
one question the generalizability of the data.
In conclusion, this study provided a reasonable range for
the MCID of EORTCQLQ-CIPN20, and the estimates can be
applied as a measure to assist in the interpretation of clinical
relevance in patient-reported neuropathy symptoms and sam-
ple size estimates for future studies. An increase of 2.5 to 5.9
points on the sensory subscale and an increase 2.6 to 5.0
points on the motor subscale were established as the smallest
meaningful peripheral neuropathy. These established values
would allow clinicians and researchers to interpret clinical
significance of neuropathy in cancer patients. These current
estimates should be further validated and refined by the use of
larger data sets and other recommended methodological ap-
proaches and on different cancer patient groups.
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